Kornimate/medical-research-clean huggingface dataset:
a randomized clinical trail of the effect of postoperative uric acid control on stone recurrence and renal function in patients with hyperuricemia of urolithiasis.

Conditions: Hypouricemia, Renal; Urolithiasis

Summary: the purpose of this study was to explore the effects of uric acid control on stone recurrence and renal function in patients with calculi of hyperuricemia through a prospective controlled study.

2020.1 -2020.12 patients with urolithiasis and hyperuricemia were enrolled in the urology department of our hospital (100 cases). the patients were informed of this study before operation and randomly divided into uric acid drug control group (n = 50) and non-drug control group (n = 50). the patients were followed up for 3 months, 6 months, 12 months and 18 months after operation. informations as age, sex, height, weight, calculation bmi, past medical history, history of gout, diabetes, hyperthyroidism, calcium supplements will be recorded. rapid blood glucose, serum total cholesterol, high density cholesterol, thyroid hormone detection, androgen, estrogen detection, serum sodium, potassium, chlorine, calcium, magnesium, phosphorus, serum uric acid will be tested. renogram test to evaluate the change of single renal function. the stones burden will be followed-up with ultrasound or kub or ct plain scan.

Eligibility criteria:
inclusion criteria: * .over 18 years old, under 70 years old, regardless of sex .the subjects had no mental illness or language dysfunction, could understand the situation of this study and had signed an informed consent form. .no clinical manifestations of urinary tract infection, urinary routine examination showed urinary tract infection, but urinary etiology test was negative (urinary routine leukocytosis), treated with broad-spectrum antibiotics for more than 3 days. .clinical manifestations of urinary tract infection, urine routine examination showed urinary tract infection, and patients with positive urinary etiology were treated with sensitive antibiotics for more than 7 days. * serum uric acid value ≥480 µmol / l * urinary stones exclusion criteria: * transplanted kidney * fever or urinary tract infection is not treated according to the inclusion criteria * pregnant women and female menstruation * unable to tolerate anesthesia or surgery due to severe systemic disease, heart disease, pulmonary insufficiency and important organ failure * patients with renal insufficiency clcr \<30 ml/min * those who take side effects of febuxostat，patients with side effects of febuxostat, patients with a previous history of coronary heart disease

Keywords: stone prevention renal function febuxostat
68ga-psma-11 pet/mri in finding tumors in patients with intermediate or high-risk prostate cancer undergoing surgery

Conditions: Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma

Summary: this phase 2-3 trial studies the utility of 68-gallium (68ga)-prostate-specific membrane antigen 11 (psma-11) positron emission tomography/magnetic resonance imaging (pet/mri) to find tumors in patients with prostate cancer who are undergoing resection surgery for prostate cancer that is prognostically expected to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). diagnostic procedures, such as pet/mri, may help find and diagnose prostate cancer, and reveal out how far the disease has spread. radioactive drugs, such as 68ga-psma-11, may bind to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (ct) or mri scan.

objectives: 1. to evaluate 68ga-psma-11 pet/mri for detection of tumor metastases in patients with intermediate and high-risk prostate cancer scheduled to undergo prostatectomy with lymph node dissection. 2. to assess sensitivity (positive predictive value) and specificity (negative predictive value) of 68ga-psma-11 pet/mri for the detection of regional nodal metastases compared to pathology at radical prostatectomy. outline: participants will receive 68ga-psma-11 intravenously (iv). patients then undergo pet/mri after 45 minutes of administration of radiopharmaceutical injection. after completion of study, patients are followed up at 24 to 48 hours.

Eligibility criteria:
inclusion criteria * biopsy-proven prostate adenocarcinoma * planned prostatectomy with lymph node dissection * intermediate- to high-risk disease (as determined by elevated prostate-specific antigen (psa) \[psa \> 10\], t stage \[t2b or greater\], gleason score \[gleason score \> 6\] or other risk factors) * karnofsky performance status of ≥ 50 \[or eastern cooperative oncology group (ecog)/world health organization (who) equivalent\] * diagnostic ct or mri performed within 90 days of the research pet * able to provide written consent exclusion criteria * patients not capable of getting pet study due to weight, claustrophobia, or inability to lay still for the duration of the exam * neoadjuvant chemotherapy or radiation therapy prior to prostatectomy, including focal ablation techniques (hifu) * androgen deprivation therapy or other neoadjuvant treatments prior to pet imaging and surgery * metallic implants (contraindicated for mri)
the co2re® system for vulvar lichen sclerosus

Conditions: Vulvar Lichen Sclerosus

Summary: subjects with vulvar lichen sclerosus (vls) will undergo fractional carbon dioxide (co2) laser treatment to the vulvar area. subjects will be evaluated for changes in clinical signs and architectural changes associated with vls at designated follow-ups to 1-year post treatment series.

this study is a prospective, non-randomized, single-group assignment, interventional clinical trial. female subjects with vulvar lichen sclerosus (vls) supported by histologic findings on biopsy and/or clinical signs on physical examination and recalcitrant to mid- to high-potency steroid therapy, will undergo up to 5 monthly treatments to the vulva with a fractional co2 laser. investigators will assess clinical signs and architectural changes associated with vls. baseline measurements will be compared to follow-up at 6 weeks, 3 months, 6 months and 12 months after the final treatment. subjects will self report sexual function using a validated fsfi questionnaire at baseline and at the 3- and 6-month follow-ups.

Eligibility criteria:
inclusion criteria: 1. able to read, understand and sign informed consent for study participation; 2. female subjects with age 18-80 years; 3. biopsy demonstrates biopsy-proven lichen sclerosus and/or there are characteristic changes for vulvar lichen sclerosus on physical examination; 4. treatment of ls has been recalcitrant to mid to high-potent topical corticosteroid treatment or subject refuses topical corticosteroid treatment. recalcitrance to therapy is defined as no response to topical corticosteroids of an adequate potency (i.e. clobetasol propionate 0.05% ointment or other steroids) and a sufficient duration (12 weeks of use) or lack of symptomatic control of the disease with a maintenance therapy; 5. topical corticosteroid treatment, if any, will be continued during the study period; 6. exogenous hormone treatment, if any, will be continued during the study period (type and dose must stay consistent throughout the study); 7. one or more of the following symptoms: itch; pain unrelated to intercourse; pain, skin tearing or bleeding with intercourse; changes/decrease in sexual function; 8. no breaks, tears or lesions, malodorous discharge or strawberry cervix present on gynecological exam. exclusion criteria: 1. presence of clinically atypical appearing nevi in the area to be treated; 2. unexplained vaginal bleeding; 3. active infection, specifically: urinary tract infection, vulvar or vaginal infection (candidiasis, genital herpes/herpes simplex virus, bacterial vaginosis, trichomonas); 4. history of vulvar or any gynecological malignancy, as well as history of pelvic radiation therapy or stem cell transplant; 5. pelvic organ prolapse \> stage 2; 6. pregnancy or planning pregnancy during the study; 7. systemic treatment with immuno-modulatory drugs. 8. use of vaginal dilators during study.

Keywords: vulvar dystrophy vulvar atrophy persistent itching leukoplakia hyperkeratosis sexual function
improving birth outcomes in bangladesh

Conditions: Birth Weight; Small for Gestational Age at Delivery; Diet; Deficiency; Gestational Weight Gain

Summary: maternal undernutrition is a global public health problem with far-reaching effects for both mothers and infants. poor maternal nutrition negatively affects fetal growth and development. both micro and macro-nutrients are required for the physiological changes and increased metabolic demands during pregnancy, including fetal growth and development. women in bangladesh have poor diets and are struggling to meet their nutrient requirements, especially during pregnancy and lactation when requirements are higher. maternal undernutrition during pregnancy is associated with a range of adverse birth outcomes, including stillbirths, preterm births, low birthweight, and small-for-gestational-age (sga) neonates, all of which remain unacceptably high in bangladesh. social protection provides a promising platform on which to leverage improvements in nutrition at scale, but current evidence on the impacts of social protection on birth outcomes is limited: few studies have been conducted and some of these studies suffer from methodological limitations. the planned study will contribute to filling this knowledge gap. an additional motivation for the study is provided by the recent who 2016 antenatal care guidelines. the guidelines call for studies on the effectiveness of alternatives to providing energy and protein supplements to pregnant women (which is recommended in undernourished populations). studying the effectiveness of providing combinations of food and cash will help build this evidence base. a third reason to conduct the study is that both food transfers and cash transfers are commonly used policy instruments in bangladesh, and the choice of intervention components to scale up in the cbp will be guided by the findings from this pilot study. the study findings will thus be highly policy relevant. a three-arm cluster-randomized, non-masked, community-based, longitudinal trial will be used. groups of pregnant women will be randomly assigned to one of three study arms providing different combinations of cash and food transfers.


Eligibility criteria:
inclusion criteria: * pregnant with their first or second child (in case of death of the first or second child during pregnancy or within two years of birth, the mother will be eligible during her third pregnancy); * in possession of a valid nid (or a nid application acknowledgement). * meeting the eligibility criteria of the government of bangladesh' mother and child benefit programme (mcbp)
study of safety, tolerability, and anti-viral effect of locteron compared to peg-intron in patients with chronic hepatitis c

Conditions: Hepatitis C

Summary: the purposes of the plus study were to confirm the safety and tolerability of two doses of locterontm (320 ug and 640 ug) dosed over four weeks in patients who had failed prior anti-hcv therapies (panels a and b), and then to continue to study the safety, tolerability, and preliminary efficacy of the same two doses of locterontm (320 ug and 640 ug) in treatment-naïve genotype 1 hcv patients when locteron dosed over 12 weeks (panel c). all subjects were also to receive oral daily weight-based ribavirin.

panels a and b of the plus study were designed to assess the safety and tolerability, pharmacokinetics, and viral kinetics over four weeks of two doses of locteron™ (230 ug and 640 ug) given every two weeks in comparison with pegintron® given weekly in treatment-experienced subjects with chronic hepatitis c of any genotype who were co-administered weight-based oral ribavirin. the two cohorts of 16 subjects each in panels a and b consisted of subjects who had failed prior interferon therapy. in panel a, 8 subjects were randomized to and completed 4 weeks of treatment with 320 μg locteron™ and 8 subjects were randomized to and completed 4 weeks of treatment with 1.5 ug/kg pegintron®. in panel b, 8 subjects were randomized to and completed 4 weeks of treatment with 640 μg locteron™ and 8 subjects were randomized to and completed 4 weeks of treatment with 1.5 ug/kg pegintron®. when the results of panel a and panel b were known, conduct of panel c for 12 weeks in treatment-naive patients with chronic genotype-1 hcv was considered unnecessary and cancelled, and an entirely new study was begun instead.

Eligibility criteria:
inclusion criteria: * evidence of chronic hepatitis c * positive hcv rna test with a level \>= 1 x 104 iu/ml (by rt-pcr) exclusion criteria: * decompensated liver disease * positive test for serum antibodies to the human immunodeficiency virus (hiv), hepatitis a (hav-igm), o hepatitis b (hbv- +hepatitis b surface antigen) * a history of severe psychiatric disease, including major depression * a history of immunologically-mediated disease, copd, severe asthma, severe cardiac disease, active cancer or cancer within last 5 years, seizures within the past 5 years or epilepsy, solid organ or bone marrow transplant, uncontrolled thyroid disease, or clinically significant retinopathy * pregnant or lactating females

Keywords: antimetabolites virus diseases anti-infective agents rna virus infections digestive system diseases flaviviridae infections antineoplastic agents therapeutic uses antiviral agents molecular mechanisms of action pharmacologic actions
daily chlorexidine bath for health care associated infection prevention

Conditions: Health Care Associated Infection; Ventilator Associated Pneumonia; Central Line-associated Bloodstream Infection (CLABSI); Catheter-Associated Urinary Tract Infection

Summary: cluster randomized controlled trial comparing two bathing strategies in critically ill patients. the intervention group will receive daily bathing with chlorhexidine. the control group will receive usual care.

healthcare-associated infections (hai) are common complications in critically ill patients and are associated with increased costs, higher length of stay, and higher morbimortality. data shows that daily chlorhexidine baths might be associated with lower hai rates in a broad population of critically ill patients. the purpose of this trial is to evaluate the effect of daily bathing with chlorhexidine compared to usual baths (soap and water) on hai in critically ill patients.

Eligibility criteria:
inclusion criteria: * all patients ≥ 18 years/old admitted to the participants's icus exclusion criteria: * history of chlorhexidine allergy
steps to health: targeting obesity in the health care workplace

Conditions: Overweight; Obese

Summary: the proposal of this study is to compare the effectiveness of two worksite weight management programs at duke: steps to health (sth) ('usual standard of care') and the more extensive steps to health plus! (sth+). we have added an additional follow-up, by invitation only, for participants in the study who agreed to be contacted for future research.

steps to health and steps to health plus! aim to help duke employees achieve weight loss and maintain healthy weights. we will be following participants in these programs over a two year period. these two groups will be compared with an observational comparison group of employees who meet eligibility criteria but do not take part in the randomized controlled trial. we will assess whether the two programs decrease obesity-related injuries in the workplace and estimate the net costs of the two programs relative to their effectiveness more broadly. in the additional follow-up, we will be assessing factors that may be related to program success. this will include a survey as well as some focus group data.

Eligibility criteria:
inclusion criteria: * completion of a health risk assessment * bmi ≥ 30 * able to read and understand study materials which are presented in english * no plans to leave duke in the next year * enrolled in one of the duke health plans * not currently pregnant exclusion criteria: * enrolled in the other available individual intervention programs (hypertension, cholesterol or pre-diabetes) * enrolling in one of the lfl weight management programs in order to qualify for bariatric surgery

Keywords: weight management employee health
endocan biomarker level in gingival crevicular fluid in periodontitis patients with type 2 diabetes mellitus

Conditions: Periodontitis; Diabetes Mellitus

Summary: aim of the current study was to evaluate endocan biomarker level in gingival crevicular fluid of patients with stage 1 or 2 (mild to moderate) periodontitis with controlled type 2 diabetes mellitus (dm) and compare it to that in dm free periodontitis patients.


Eligibility criteria:
inclusion criteria: * probing pocket depths (ppd) ≤ 5 mm. * clinical attachment level (cal) ≤ 4 mm. * type 2 dm, for at least the past 3 years. * hba1c ≤ 7%. exclusion criteria: * uncontrolled diabetes mellitus. * systemic antibiotic or anti-inflammatory medication use in the previous 2 months. * non-surgical periodontal therapy in the previous 6 months. * surgical periodontal therapy in the previous 12 months. * use of calcium channel blockers, phenytoin, or cyclosporine. * pregnancy. * smokers
a study of jaktinib for the treatment of steroid-refractory acute graft-versus-host disease.

Conditions: Acute Graft-Versus-Host Disease

Summary: this is an single-arm, phase ii multi-center study. the purpose of this study is to assess the efficacy and safety of jaktinib in subjects with grades ii to iv steroid-refractory acute graft-versus-host disease.


Eligibility criteria:
inclusion criteria: * have undergone first allogeneic hematopoietic stem cell transplantation (allo-hsct) from any donor source using bone marrow, peripheral blood stem cells, or cord blood for hematologic malignancies. recipients of nonmyeloablative and myeloablative conditioning regimens are eligible. * clinically suspected grades ii to iv acute gvhd according to nccn guidelines 2020 v2.0, occurring after allo-hsct with any conditioning regimen and any anti-gvhd prophylactic program. * subjects with steroid-refractory acute gvhd, defined as any of the following: subjects with progressive gvhd (ie, increase in stage in any organ system or any new organ involvement) after 3-5 days of primary treatment with methylprednisolone ≥ 2 mg/kg per day (or equivalent) ± calcineurin inhibitors（cni）；subjects with gvhd that has not improved (ie, decrease in stage in at least 1 involved organ system) after 5-7 days of primary treatment with methylprednisolone ≥ 2 mg/kg per day (or equivalent) ± calcineurin inhibitors（cni）；subjects who corticosteroid dependence（ie, begin corticosteroids at 2.0 mg/kg per day, demonstrate response, but progress before decrease from the initial starting dose of corticosteroids is achieved）. * ecog: 0-2； * life expectancy \> 4 weeks； * ability for oral drug intake； * willingness to comply with all study visits and procedures. exclusion criteria: * has received more than 2 allo-hsct. * acute gvhd occurring after non-scheduled donor leukocyte infusion (dli) administered. * has received more than 1 systemic treatment in addition to corticosteroids for acute gvhd. * presence of an active uncontrolled infection. * serum creatinine \> 1.5 uln or creatinine clearance \< 30 ml/min calculated by cockcroft-gault equation. * known allergies, hypersensitivity, or intolerance to any of the study medications, excipients, or similar compounds.

Keywords: gvhd
hpv prevalence in transpersons - a prospective study

Conditions: Papillomavirus Infection; Transsexualism

Summary: in this study, human papilloma virus (hpv) prevalence will be determined once in the urine of 200 trans people. in addition, subjects will be asked to complete a questionnaire about their sexual orientation, which is adapted from the largest published study.

all transpeople who visit the outpatient clinic are asked to participate in the study. after being informed and signing the informed consent form, the subjects are asked to give first-void urine and fill out the survey. the urine samples are sent pseudonymously to the university of ljubljana for analysis. the subjects will be informed about their results within 3 weeks.if the result is positive, the subjects will be offered voluntary further care in our hpv outpatient clinic. however, this will take place outside the study. the data collected there can be used for further analyses.

Eligibility criteria:
inclusion criteria: * transpeople * age over 18 years * sufficient knowledge of german exclusion criteria: * age under 18 years * insufficient knowledge of german
augmented reality for the visually impaired - part 1

Conditions: Retinitis Pigmentosa; Glaucoma

Summary: the main objective of this study is to quantify vision parameters in subjects with concentric visual field constriction, and this in relation to the display on virtual reality goggles. more specifically: * the maximum brightness value for visual comfort (threshold_max) * the minimum value of the perceptible light contrast in low light perceptible (threshold_min) * the speed of light change adaptation in the range \[threshold_max-threshold_min\] and \[threshold_min-threshold_max\].

secondary objectives are to: a. quantifying the device parameters "rv glasses + camera" depending on visual acuity and the visual field of each subject: * optimal extent of the visual field provided by the device "rv glasses + camera". b. measuring the effectiveness of different image processing algorithms used in the development of the software part of this technical assist device: * capture and display hdr images (high dynamic range) * color adjustment.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the subject is suffering from retinitis pigmentosa or glaucoma with concentric visual field constriction and presents with: * an acuity in the better eye superior or equal to 1/10 in near vision, * a binocular field of between 1° and 30°, * a good central fixation, absence of central scotoma, * motor capability for using a computer keyboard with one hand. exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, or under guardianship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * subjects with (or evolving toward) a multiple sensory disability, or one including cognitive disorders